These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2444444)

  • 1. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.
    Drukarch B; Kits KS; Van der Meer EG; Lodder JC; Stoof JC
    Eur J Pharmacol; 1987 Sep; 141(1):153-7. PubMed ID: 2444444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THA increases action potential duration of central histamine neurons in vitro.
    Reiner PB; McGeer EG
    Eur J Pharmacol; 1988 Oct; 155(3):265-70. PubMed ID: 3148476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease.
    Drukarch B; Leysen JE; Stoof JC
    Life Sci; 1988; 42(9):1011-7. PubMed ID: 2893967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
    Mesulam MM; Geula C; Morán MA
    Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats.
    Xiao WB; Nordberg A; Zhang X
    J Pharmacol Exp Ther; 1993 May; 265(2):759-64. PubMed ID: 8496822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro.
    Hunter AJ; Murray TK; Jones JA; Cross AJ; Green AR
    Br J Pharmacol; 1989 Sep; 98(1):79-86. PubMed ID: 2804555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones.
    Halliwell JV; Grove EA
    Eur J Pharmacol; 1989 Apr; 163(2-3):369-72. PubMed ID: 2721578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA).
    Cumming P; Reiner PB; Vincent SR
    Biochem Pharmacol; 1990 Sep; 40(6):1345-50. PubMed ID: 2403387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms.
    Robinson TN; De Souza RJ; Cross AJ; Green AR
    Br J Pharmacol; 1989 Dec; 98(4):1127-36. PubMed ID: 2611486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes.
    Palmieri DA; Butterfield DA
    Prog Clin Biol Res; 1989; 292():419-24. PubMed ID: 2726917
    [No Abstract]   [Full Text] [Related]  

  • 11. 9-Amino-1,2,3,4-tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels.
    Osterrieder W
    Br J Pharmacol; 1987 Nov; 92(3):521-5. PubMed ID: 2447986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices.
    Loiacono RE; Mitchelson FJ
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Jul; 342(1):31-5. PubMed ID: 2402302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?
    Nilsson L; Adem A; Hardy J; Winblad B; Nordberg A
    J Neural Transm; 1987; 70(3-4):357-68. PubMed ID: 3681290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.
    Nielsen JA; Mena EE; Williams IH; Nocerini MR; Liston D
    Eur J Pharmacol; 1989 Nov; 173(1):53-64. PubMed ID: 2606156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
    Nordberg A; Nilsson-Håkansson L; Adem A; Lai Z; Winblad B
    Prog Clin Biol Res; 1989; 317():1169-78. PubMed ID: 2557636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An electrophysiological study of 9-amino-1,2,3,4-tetrahydroacridine (THA) on sino-atrial node preparations of rabbits.
    Kotake H; Noguchi N; Doi T; Matsuoka S; Hisatome I; Hasegawa J; Mashiba H
    Gen Pharmacol; 1990; 21(4):489-92. PubMed ID: 2379801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum.
    Clarke PB; Reuben M; el-Bizri H
    Br J Pharmacol; 1994 Mar; 111(3):695-702. PubMed ID: 8019748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
    Flynn DD; Mash DC
    J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of 1,2,3,4-tetrahydro-9-aminoacridine on the depolarization-induced release of GABA from cerebral cortex.
    de Belleroche J; Gardiner IM
    Br J Pharmacol; 1988 Aug; 94(4):1017-9. PubMed ID: 3207970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase.
    Adem A; Jossan SS; Oreland L
    Neurosci Lett; 1989 Dec; 107(1-3):313-7. PubMed ID: 2616041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.